These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 9829884)

  • 1. Platelet glycoprotein IIb/IIIa receptor blockade therapy for large coronary aneurysms and thrombi in Kawasaki disease.
    Etheridge SP; Tani LY; Minich LL; Revenaugh JR
    Cathet Cardiovasc Diagn; 1998 Nov; 45(3):264-8. PubMed ID: 9829884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does Abciximab enhance regression of coronary aneurysms resulting from Kawasaki disease?
    Williams RV; Wilke VM; Tani LY; Minich LL
    Pediatrics; 2002 Jan; 109(1):E4. PubMed ID: 11773572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet glycoprotein IIb/IIIa receptor blockade in acute myocardial infarction associated with thrombotic occlusion of the left main coronary artery.
    Rechavia E; Wurzel M
    Circulation; 1998 Sep; 98(12):1249-50. PubMed ID: 9743517
    [No Abstract]   [Full Text] [Related]  

  • 4. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
    EPISTENT Investigators
    Lancet; 1998 Jul; 352(9122):87-92. PubMed ID: 9672272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade.
    Ghaffari S; Kereiakes DJ; Lincoff AM; Kelly TA; Timmis GC; Kleiman NS; Ferguson JJ; Miller DP; Califf RA; Topol EJ
    Am J Cardiol; 1998 Jul; 82(1):7-12. PubMed ID: 9671000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
    Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.
    Lincoff AM; Tcheng JE; Califf RM; Kereiakes DJ; Kelly TA; Timmis GC; Kleiman NS; Booth JE; Balog C; Cabot CF; Anderson KM; Weisman HF; Topol EJ
    Circulation; 1999 Apr; 99(15):1951-8. PubMed ID: 10208997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimizing bleeding complications of percutaneous coronary intervention and glycoprotein IIb-IIIa antiplatelet therapy.
    Juran NB
    Am Heart J; 1999 Oct; 138(4 Pt 2):297-306. PubMed ID: 10502235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of coronary artery aneurysms using abciximab in children with Kawasaki disease.
    Bachlava E; Loukopoulou S; Karanasios E; Chrousos G; Michos A
    Int J Cardiol; 2016 Oct; 220():65-9. PubMed ID: 27372045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A child with Kawasaki disease who survived after rupture of a coronary artery aneurysm.
    Mok GC; Sung RY; Yam MC; Arifi AA; Lam WW; Fok TF
    Eur J Pediatr; 2003 Sep; 162(9):634-6. PubMed ID: 12811552
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of platelet glycoprotein IIb/IIIa inhibition with abciximab on thrombin generation and activity during percutaneous coronary intervention.
    Dangas G; Marmur JD; King TE; De Leon J; Sharma SK; Vidhun R; Feldman D; Stoynov MY; Badimon JJ; Ambrose JA
    Am Heart J; 1999 Jul; 138(1 Pt 1):49-54. PubMed ID: 10385763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.
    Lincoff AM; Bittl JA; Harrington RA; Feit F; Kleiman NS; Jackman JD; Sarembock IJ; Cohen DJ; Spriggs D; Ebrahimi R; Keren G; Carr J; Cohen EA; Betriu A; Desmet W; Kereiakes DJ; Rutsch W; Wilcox RG; de Feyter PJ; Vahanian A; Topol EJ;
    JAMA; 2003 Feb; 289(7):853-63. PubMed ID: 12588269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extensive coronary aneurysms with thrombosis in resistant Kawasaki disease.
    Sivakumar K; Pavithran S
    Pediatr Cardiol; 2013 Feb; 34(2):444-6. PubMed ID: 22427313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of improved antithrombotic and antiplatelet agents: genesis of the Comparison of Abciximab Complications with Hirulog [and back-Up Abciximab] Events Trial (CACHET).
    Topol EJ
    Am J Cardiol; 1998 Oct; 82(8B):63P-68P. PubMed ID: 9809894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Images in cardiovascular medicine. Rapid dissolution of massive intracoronary thrombosis with platelet glycoprotein IIb/IIIa receptor inhibitor.
    Rerkpattanapipat P; Kotler MN; Yazdanfar S
    Circulation; 1999 Jun; 99(22):2965. PubMed ID: 10359744
    [No Abstract]   [Full Text] [Related]  

  • 16. Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis.
    Claeys MJ; Van der Planken MG; Bosmans JM; Michiels JJ; Vertessen F; Van Der Goten P; Wuyts FL; Vrints CJ
    Eur Heart J; 2005 Mar; 26(6):567-75. PubMed ID: 15618034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.
    EPILOG Investigators
    N Engl J Med; 1997 Jun; 336(24):1689-96. PubMed ID: 9182212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention.
    Madan M; Berkowitz SD; Christie DJ; Jennings LK; Smit AC; Sigmon KN; Glazer S; Tcheng JE
    Am Heart J; 2001 Feb; 141(2):226-33. PubMed ID: 11174336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful Treatment of Myocardial Infarction in an Infant With Kawasaki Disease.
    Jone PN; Tapia D; Davidson J; Fagan TE; Browne L; Ing RJ; Kay J
    Semin Cardiothorac Vasc Anesth; 2015 Sep; 19(3):255-9. PubMed ID: 25700695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithrombotic assessment of the effects of combination therapy with the anticoagulants efegatran and heparin and the glycoprotein IIb-IIIa platelet receptor antagonist 7E3 in a canine model of coronary artery thrombosis.
    Shetler TJ; Crowe VG; Bailey BD; Jackson CV
    Circulation; 1996 Oct; 94(7):1719-25. PubMed ID: 8840866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.